Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12.
Saved in:
| Title: | Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12. |
|---|---|
| Authors: | Kurokawa C; Virology and Vaccine Discovery, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Agrawal S; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Mitra A; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Galvani E; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Cambridge, UK., Burke S; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Cambridge, UK., Varshine A; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Rothstein R; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Schifferli K; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Monks NR; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Foloppe J; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Silvestre N; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Quemeneur E; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Demeusoit C; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Kleinpeter P; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Sapra P; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Barrett C; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Hammond SA; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Kelly EJ; Clinical Virology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Laliberte J; Virology and Vaccine Discovery, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Durham NM; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Oberst M; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Broggi MAS; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA. |
| Source: | Molecular therapy. Oncology [Mol Ther Oncol] 2024 Jan 10; Vol. 32 (1), pp. 200758. Date of Electronic Publication: 2024 Jan 10 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9918752083706676 Publication Model: eCollection Cited Medium: Print ISSN: 2950-3299 (Print) Linking ISSN: 29503299 NLM ISO Abbreviation: Mol Ther Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
